🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Chongqing Peg-Bio Biopharm clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Chongqing Peg-Bio Biopharm as lead sponsor. Synced 26 Sep 2026
6Current trials
6Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Chongqing Peg-Bio Biopharm is the lead sponsor of 6 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Phase 1. The most-studied condition is Short Bowel Syndrome.

ClinicalTrials.gov trials by status

  • Recruiting6100%

Trials by phase

  • Phase 1350%
  • Phase 2117%
  • Phase 3117%
  • Phase 1/2117%
01

Clinical trials sponsored by Chongqing Peg-Bio Biopharm

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Clinical Study of FT1 in Patients With Short Bowel Syndrome
NCT07704047 · ClinicalTrials.gov ↗ · Short Bowel Syndrome, SBS
Phase 2 Recruiting 2026-08 China
A Clinical Study on the Safety and Tolerability of PL54 Injection in Adult Patients With Phenylketonuria (PKU)
NCT07672756 · ClinicalTrials.gov ↗ · Phenylketonuria (PKU)
Phase 1 Recruiting 2025-07 China
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
NCT07702162 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Cancer
Phase 1 Recruiting 2025-11 China
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584 · ClinicalTrials.gov ↗ · Short Bowel Syndrome
Phase 3 Recruiting 2024-09 China
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
NCT07446491 · ClinicalTrials.gov ↗ · Thrombocytopenia Associated With Chronic Liver Disease
Phase 1/2 Recruiting 2025-06 China
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia (ITP)
Phase 1 Recruiting 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Chongqing Peg-Bio Biopharm trials

7 conditions
Short Bowel Syndrome2SBS1Phenylketonuria (PKU)1Advanced Solid Tumors1Cancer1Thrombocytopenia Associated With Chronic Liver Disease1Primary Immune Thrombocytopenia (ITP)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China66

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Short Bowel Syndrome

SponsorTrials
Zealand Pharma1
Shire1

Sponsors with the most current trials registered for this condition.

05

Questions about Chongqing Peg-Bio Biopharm trials

How many clinical trials does Chongqing Peg-Bio Biopharm sponsor?

Chongqing Peg-Bio Biopharm is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chongqing Peg-Bio Biopharm trials recruiting?

Yes. 6 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.